Aelis IPO raises 25 million euros for brain diseases mission
French biopharma Aelis Farma has raised 25 million euros ($28.4 million) in an initial public offering (IPO).
Aelis achieved its objective in the IPO and now has a market capitalization of approximately 175 million euros. It is expected to start trading on the regulated market of Euronext Paris on Friday, under the mnemonic AELIS.
"A leading player in the field of brain diseases"The Bordeaux-based firm is developing a new class of drugs, signaling specific inhibitors of the CB1 receptor (CB1-SSi) of the endocannabinoid system, which provide access to several therapeutic areas without available treatments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze